MedTrace Logo

Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma

NCT07379489 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2026-01-30

No results posted yet for this study

Summary

Early hepatocellular carcinoma (HCC) recurrence (driven by residual tumors) and late recurrence (driven by de novo tumors) exhibit distinct biological behaviors, suggesting differential therapeutic vulnerabilities. The beneficiaries of adjuvant PD-1 inhibitors (aPD-1) and their efficacy across these temporally divergent recurrence patterns remains unestablished.

Conditions

  • HCC
  • Adjuvant Therapy
  • Recurrence
  • Immune Checkpoint Inhibitor

Interventions

DRUG

PD-1 Inhibitors

Patients in the adjuvant cohort received at least one cycle of PD-1 inhibitors.

Sponsors & Collaborators

  • Tongji Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-31
Primary Completion
2029-12-31
Completion
2031-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07379489 on ClinicalTrials.gov